The estimated Net Worth of Barbara Weber is at least $1.46 Миллион dollars as of 1 September 2023. Barbara Weber owns over 15,000 units of Revolution Medicines Inc stock worth over $1,284,170 and over the last 4 years he sold RVMD stock worth over $0. In addition, he makes $174,706 as Independent Director at Revolution Medicines Inc.
Sign up
Barbara Weber RVMD stock SEC Form 4 insiders trading
Barbara has made over 6 trades of the Revolution Medicines Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of RVMD stock worth $57,000 on 1 September 2023.
The largest trade he's ever made was exercising 15,000 units of Revolution Medicines Inc stock on 1 September 2023 worth over $57,000. On average, Barbara trades about 3,556 units every 93 days since 2020. As of 1 September 2023 he still owns at least 30,825 units of Revolution Medicines Inc stock.
You can see the complete history of Barbara Weber stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Barbara Weber biography
Dr. Barbara Weber M.D. serves as Independent Director of the Company. Since September 2017, Dr. Weber has served as the President and Chief Executive Officer of Tango Therapeutics, Inc., a biotechnology company. Dr. Weber has been a Venture Partner at Third Rock Ventures since March 2015 and from April 2015 to September 2017 she served as Interim Chief Executive Officer at Neon Therapeutics, Inc., a biotechnology company. From 2009 to February 2015, Dr. Weber served as Senior Vice President, Oncology Translation Medicine at Novartis. Dr. Weber received a B.S. in Chemistry from the University of Washington and an M.D. from the University of Washington School of Medicine and was a resident in internal medicine at Yale University. Weber’s experience as an officer and director of other biotechnology companies and her educational background provide her with the qualifications and skills necessary to serve as a member of our board of directors.
What is the salary of Barbara Weber?
As the Independent Director of Revolution Medicines Inc, the total compensation of Barbara Weber at Revolution Medicines Inc is $174,706. There are 11 executives at Revolution Medicines Inc getting paid more, with Mark Goldsmith having the highest compensation of $4,576,250.
What's Barbara Weber's mailing address?
Barbara's mailing address filed with the SEC is C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY, CA, 94063.
Insiders trading at Revolution Medicines Inc
Over the last 5 years, insiders at Revolution Medicines Inc have traded over $249,645,422 worth of Revolution Medicines Inc stock and bought 3,371,315 units worth $74,500,278 . The most active insiders traders include Peter Svennilson, Thilo Schroeder и Rock Ventures Ii, L.P.Third.... On average, Revolution Medicines Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,075,216. The most recent stock trade was executed by Stephen Michael Kelsey on 13 August 2024, trading 16,667 units of RVMD stock currently worth $68,168.
What does Revolution Medicines Inc do?
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
What does Revolution Medicines Inc's logo look like?
Complete history of Barbara Weber stock trades at Revolution Medicines Inc
Revolution Medicines Inc executives and stock owners
Revolution Medicines Inc executives and other stock owners filed with the SEC include:
-
Mark Goldsmith,
Chairman of the Board, President, Chief Executive Officer -
Margaret Horn,
Chief Operating Officer, General Counsel -
Steve Kelsey,
President of Research and Development -
Dr. Mark A. Goldsmith Ph.D.,
CEO, Pres & Chairman -
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.,
Pres of R&D -
Margaret A. Horn J.D.,
COO, Gen. Counsel & Sec. -
Dr. Stephen M. Kelsey M.D., FRCP, FRC Path.,
Pres of R&D -
Margaret A. Horn,
COO, Gen. Counsel & Sec. -
Xiaolin Wang,
Exec. VP of Clinical Devel. -
Dr. Mark A. Goldsmith M.D., Ph.D.,
CEO, Pres & Chairman -
Alexis Borisy,
Lead Independent Director -
Barbara Weber,
Independent Director -
Vincent Miller,
Independent Director -
Elizabeth Anderson,
Independent Director -
Peter Svennilson,
Independent Director -
Thilo Schroeder,
Independent Director -
Eric Schmidt,
Independent Director -
Neil Exter,
Independent Director -
Jack Anders,
Vice President - Finance and Principal Accounting Officer -
Dr. Martin D. Burke M.D., Ph.D.,
Co-Founder & Chairman of Scientific Advisory Board -
Jack Anders,
Sr. VP of Fin. & Principal Accounting Officer -
Luan M. Wilfong,
Sr. VP of HR -
Walter Reiher Ph.D.,
Chief Information Officer -
David L. Pompliano,
Founding Chief Scientific Officer -
Dr. Kevan M. Shokat,
Academic Co-Founder & Member of Scientific Advisory Board -
Dr. Michael A. Fischbach,
Academic Co-Founder & Member of Scientific Advisory Board -
Dr. Martin D. Burke,
Co-Founder & Chairman of Scientific Advisory Board -
Frank Clyburn,
-
Group Iii, Lpcolumn Group I...,
-
Laurence Lasky,
Director -
Group Iii, Lp Svennilson Pe...,
-
Rock Ventures Iii, L.P.Thir...,
-
Rock Ventures Iv, L.P.Third...,
-
James E Deerfield Mgmt Iv, ...,
-
Lin Wei,
Chief Medical Officer -
Jeff Cislini,
General Counsel -
Stephen Michael Kelsey,
See Remarks -
Rock Ventures Iii, L.P.Thir...,
-
Rock Ventures Iii, L.P.Thir...,
-
Xiaolin Wang,
See Remarks -
Rock Ventures Ii, L.P.Third...,
-
Rock Ventures Iii, L.P.Thir...,
-
Sushil Patel,
-
Flavia Borellini,
-
Lorence H. Kim,